Vivani Medical Reports Q3 2025 Results and Updates

Vivani Medical, Inc. ( (VANI) ) has released its Q3 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investors.

Vivani Medical, Inc. is a biopharmaceutical company specializing in the development of miniaturized, ultra long-acting drug implants, primarily targeting metabolic diseases such as obesity and type-2 diabetes. The company recently announced its third-quarter 2025 financial results and provided a business update, highlighting significant progress in its clinical programs and financial activities. During the third quarter, Vivani successfully completed the LIBERATE-1 study, marking the first clinical application of its NanoPortal™ technology, and plans to initiate a Phase 1 clinical study of its semaglutide implant for chronic weight management in 2026. The company also raised approximately $25.7 million through private placements and financings to support its development programs and secure its financial position into 2027. Financially, Vivani reported a net loss of $6.5 million for the third quarter of 2025, with increased research and development expenses contributing to the loss. Despite the financial challenges, Vivani remains focused on advancing its clinical programs and anticipates the initiation of the semaglutide implant program in 2026, while also planning the spin-off of its subsidiary, Cortigent, once regulatory conditions permit.